These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23645733)

  • 1. Broussoflavonol B restricts growth of ER-negative breast cancer stem-like cells.
    Guo M; Wang M; Zhang X; Deng H; Wang ZY
    Anticancer Res; 2013 May; 33(5):1873-9. PubMed ID: 23645733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel anticancer agent Broussoflavonol B downregulates estrogen receptor (ER)-α36 expression and inhibits growth of ER-negative breast cancer MDA-MB-231 cells.
    Guo M; Wang M; Deng H; Zhang X; Wang ZY
    Eur J Pharmacol; 2013 Aug; 714(1-3):56-64. PubMed ID: 23769740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broussoflavonol B from
    Jeong JH; Ryu JH
    Molecules; 2020 May; 25(10):. PubMed ID: 32429421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ER-α variant ER-α36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells.
    Deng H; Yin L; Zhang XT; Liu LJ; Wang ML; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():417-26. PubMed ID: 25158023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
    Zhang X; Deng H; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.
    Deng H; Zhang XT; Wang ML; Zheng HY; Liu LJ; Wang ZY
    PLoS One; 2014; 9(2):e88034. PubMed ID: 24558373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells.
    Pan X; Zhao B; Song Z; Han S; Wang M
    J Pharmacol Sci; 2016 Feb; 130(2):85-93. PubMed ID: 26810571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
    Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
    Zhang X; Wang ZY
    Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer.
    Wang ZY; Yin L
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():193-206. PubMed ID: 25917453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells.
    Kurebayashi J; Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T
    Cancer Sci; 2017 May; 108(5):918-930. PubMed ID: 28211214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristic Binding Landscape of Estrogen Receptor-α36 Protein Enhances Promising Cancer Drug Design.
    Adewumi AT; Mosebi S
    Biomolecules; 2023 Dec; 13(12):. PubMed ID: 38136668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
    Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
    Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.
    Kang L; Guo Y; Zhang X; Meng J; Wang ZY
    J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):262-8. PubMed ID: 21907803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
    Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
    Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.
    Teymourzadeh A; Mansouri S; Farahmand L; Hosseinzade A; Majidzadeh-A K
    Clin Breast Cancer; 2017 Oct; 17(6):403-407. PubMed ID: 28433540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z; Barnes CJ; Kumar R
    Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.